CD200 and AL amyloidosis: Thus, patients with overexpression of CD200 on multiple myeloma cells (MMc), despite high-dose chemotherapy and ASCT, are reported to have a shorter event free-survival (EFS) compared to patients whose MMc do not overexpress CD200 [32].